Note: Descriptions are shown in the official language in which they were submitted.
CA 02370098 2000-07-28
1
Human OTrCP protein
The present invention relates to a novel human protein which is involved in
the targeting of proteins towards proteasome degradation pathways. This
protein,
called h-OTrCP, is capable of interacting notably with the Vpu protein of HIV-
1
virus and with the cell proteins IxB, P-catenin and Skplp.
The degradation of proteins by proteasome, a multiprotein complex present
in all cells, is involved in numerous essential cell phenomena such as the
control of
cell proliferation, the renewal of proteins and the removal of incorrectly
folded
proteins, particularly in the endoplasmic reticulum (CIECHANOVER A., Cell, 79,
13-21, 1994). Numerous viruses, like HIV-1 virus, which degrades CD4 via one
of
its proteins Vpu (TRONO D., Cell, 82, 189-1992, 1995), exploit these cell
pathways of protein degradation, in which the proteins are targeted towards
proteasome by various interactions with other proteins before being degraded.
To
be targeted towards and degraded by proteasome, the proteins must generally be
ubiquitinylated beforehand by ubiquitin-ligase complexes. Furthermore, to be
ubiquitinylated, the proteins must often undergo modifications such as
phosphorylations (CIECHANOVER A., Embo. J., 17, 7151-7160, 1998).
Several other proteins of the OTrCP type are known at the present time:
- the OTrCP protein of Xenope, described by Spevak et al. (Mol. Cell. Biol.,
13, 4953-4966, 1993);
- the Slimb protein of drosophila, described by Jiang et al. (Nature, vol.
391, 29 January 1998); and
- the KIAA 0696 protein identified by Ishikawa et al. (DNA Research, 5,
169-176, 1998) during a systematic analysis of sequences expressed in the
brain.
Jiang et al. showed that the Slimb protein of drosophila is involved in the
stability of the Armadillo protein and the signaling of two metabolic pathways
essential for development, namely the Hedgehog and Wingless pathways. They
also showed that the Slimb protein has a homology of about 80% with the OTrCP
protein of Xenope, none of whose functions was described by Spevak et al. As
the
P-catenin of Xenope or man, which is the homolog of the Armadillo protein of
drosophila, seems to be targeted towards proteasome degradation pathways in
the
absence of signaling of the Hedgehog and Wingless pathways, said authors
suggest
that, in man, the genes coding for the homologs of Slimb could be involved in
the
proteolytic degradation of P-catenin, a protein which acquires oncogenic
properties
CA 02370098 2000-07-28
2
when it is not degraded (POLAKIS P., Biochim. Biophys. Acta, 1332, F127-47,
1997).
However, despite the fact that conservation of the Wingless and Hedgehog
pathways in vertebrates is important, it is not certain that the functions of
the
homologous proteins will be totally conserved. Moreover, there are numerous
examples which show that there are always significant differences between
species.
Also, solely on the basis of genetic studies, Jiang et al. established the
involvement of Slimb in the control of the Wingless and Hedgehog pathways in
drosophila. Proof that this control is dependent on a direct interaction
between
Slimb and Armadillo, for example, has neither been sought nor found.
The protein according to the invention, called h-OTrCP, is capable of
interacting with virus proteins or cell proteins which can act as mediators or
be
degraded by proteasome. In particular, the h-OTrCP protein is capable of
interacting notably with the Vpu protein of HIV-1 virus and with the cell
proteins
IKB and P-catenin.
It is particularly useful for screening therapeutic agents such as, in
particular, antitumoral, antiviral, anti-inflammatory and anti-Alzheimer
agents.
The Vpu protein is a small membrane protein of 81 amino acids which is
expressed by the majority of isolates of HIV-1 virus but not by those of the
considerably less pathogenic HIV-2 virus or by those of SIV simian virus
(COHEN
et al., Nature, 334, 532-534, 1988, and STREBEL et al., Science, 2, 1221-1223,
1988).
One of the functions of the Vpu protein is its capacity to induce degradation
of the CD4 protein, a cell receptor of HIV-1 virus, so it participates in
reducing the
expression of the CD4 receptor on the cell surface (Willey et al., J. Virol.,
68,
1207-1212, 1994).
It is also known that the two phosphorylation serines of the Vpu protein,
located in positions 52 and 56, are essential for the degradation of CD4
induced by
Vpu (MARGOTTIN et al., Virology, 223, 381-386, 1996). Moreover, during the
process of infection by HIV-1 in the absence of the Vpu protein, the Gp160
envelope precursor and the newly synthesized CD4 protein combine in the
endoplasmic reticulum to block the maturation of the Gp160 protein (BOUR et
al.,
J. Virol., 65, 6387-6396, 1991). Degradation of the CD4 receptor mediated by
the
Vpu protein is essential for releasing the viral envelope protein which is
held in the
endoplasmic reticulum by being bound to CD4 through interaction with the Gp120
CA 02370098 2000-07-28
3
subunit, and for allowing the normal maturation of the envelope into the
plasmic
membrane and subsequently its integration into the virus particles, rendering
them
infectious. Recent studies have demonstrated the fact that degradation of the
CD4
receptor mediated by the Vpu protein is sensitive to specific proteasome
inhibitors
and is dependent on the presence of an "intact ubiquitinylation machinery"
(FUJITA et al., J. Gen. Virol., 78, 619-625, 1997).
Thus the Vpu protein participates in absolutely critical functions for
assuring the production of large numbers of infectious virus particles, since
it acts
not only on the products of the gag gene, i.e. on the structural proteins, to
increase
the release of the virus particles, but also on the products of the env gene
to allow
the maturation of the envelope protein following degradation of the CD4
receptor.
In 1996, MARGOTTIN et al. (supra) showed that the interaction between Vpu and
CD4 took place via their cytoplasmic domain and that this interaction was not
sufficient to trigger degradation of the CD4 receptor.
The Skplp protein is a cell protein involved in the targeting of proteins
towards proteasome degradation pathways, which depends on the ubiquitinylation
of the proteins (PICKART C.M., The Faseb Journal, 11, 1055-1066, 1997).
BAI et al. (Cell, 86, 263-274, 1996) showed that the Skplp protein was
necessary for ubiquitin-mediated proteolysis and that this degradation took
place
due to the interaction of Skplp with proteins containing a unit called F-box.
The Skplp protein is an essential factor in the targeting of cell cycle
regulatory proteins by proteasome. Targeting of the degradation of these
regulators
is particularly necessary when the cell cycle enters the S phase of DNA
synthesis
(PAGANO M., The Faseb Journal, 11, 1068-1075, 1997). Recent studies showed
that the Skplp protein and F-box proteins are the essential elements of high-
molecular complexes called SCF (Skplp-Cullin-F-box-protein complexes). These
SCF complexes play the role of enzyme E3; through their ubiquitin-ligase
activity,
they allow the last step of the ubiquitinylation of substrate proteins, which
are thus
targeted towards degradation by proteasome (HOYT A., Cell, 91, 149-151, 1997).
It is further pointed out that no Skplp homolog has yet been identified in
drosophila.
The IxB protein, which exists in different forms (a, P, c), is the major
inhibitor of the NFxB transcription factor, keeping it in the form of an
inactive
complex in the cytoplasm (Beg A. et al., Genes and Dev., 7, 2064-2070, 1993).
After stimulation of the cells by factors such as interleukin-1 (ILl) and
tumor
CA 02370098 2000-07-28
4
necrosis factor (TNF), the IxB protein is phosphorylated on serine residues
S32 and
S36. This phosphorylation leads very rapidly to the ubiquitinylation of the
protein
and to the targeting thereof towards degradation by proteasome. The active
NFKB
factor, for example in the form of two subunits P50 and P65, is then released
and
imported into the nucleus, where it will be able to activate a very large
number of
genes and cause inflammatory phenomena in particular.
The P-catenin protein is a cell protein controling the essential signal
transduction pathways such as the Wingless pathways, which are very highly
conserved in all vertebrates (MILLER et al., Genes and Dev., 10, 2527-2539,
1996,
and POLAKIS P., Biochim. Biophys. Acta, 1332, F 127-47, 1997). P-Catenin
accumulates in cancerous cells, either as a result of mutations which prevent
phosphorylation on serine residues 33 and 37 (mutated P-catenin proteins), or
as a
result of mutations of its cofactor, the APC protein, which is necessary for
its
degradation.
The accumulation of P-catenin due to its non-degradation leads to its
importation into the nucleus and to the activation of genes controlled by TCF-
LEF
promoters, causing cell proliferation and transformation phenomena.
It was recently shown that mutations of presenilin-1 in patients suffering
from Alzheimer's disease caused a destabilization and enhanced degradation of
P-
catenin (ZHANG et al., Nature, 395, 698-702, 1998). These authors showed that
non-mutated presenilin-1 binds to P-catenin and thereby contributes to its
stability.
In Alzheimer's disease, the mutated presenilin is no longer capable of binding
to P-
catenin, so the latter is degraded more rapidly. The level of P-catenin is
considerably reduced in the neuronal cells of patients suffering from
Alzheimer's
disease. The loss of P-catenin causes an enhanced apoptosis of the neuronal
cells,
which would account for the neuronal loss observed in this pathological
condition.
It is easy to see that there is an urgent need for means of modulating,
namely activating or inhibiting, the targeting of proteins towards proteasome.
A novel human protein involved in the targeting of proteins towards
proteasome degradation pathways has now been found which makes it possible to
screen modulators of the targeting of proteins towards proteasome.
The present invention therefore relates to a novel human protein, called
h-PTrCP, which has SEQ ID No. 2 and which is involved in the targeting of
proteins towards proteasome degradation pathways.
The h-PTrCP protein possesses 569 amino acids and comprises one F-box
CA 02370098 2000-07-28
and seven WD units having the following positions in the sequence SEQ ID No.
2:
- F-box: amino acids 147-191,
- first WD unit: amino acids 259-292,
- second WD unit: amino acids 304-332,
5 - third WD unit: amino acids 343-372,
- fourth WD unit: amino acids 387-415,
- fifth WD unit: amino acids 427-455,
- sixth WD unit: amino acids 467-492,
- seventh WD unit: amino acids 516-544.
Because of the homology of this novel protein with the OTrCP of Xenope, a
protein containing 0-transducin units and known as "beta transducin repeats
containing protein", the protein of the invention is called h-OTrCP (human
OTrCP).
Via its WD units, the h-PTrCP protein of the invention is capable of
interacting with proteins degradable by proteasome, particularly with virus
proteins
and cell proteins which possess the phosphorylation unit comprising the amino
acids Asp-Ser-Gly-Xaa-Xaa-Ser, in which Xaa is any natural amino acid and in
which the serine residues are phosphorylated.
The phosphorylation of this unit Asp-Ser-Gly-Xaa-Xaa-Ser is essential to
the ubiquitinylation and subsequent degradation of proteins possessing this
type of
unit. The h-OTrCP protein is only capable of interacting with proteins
containing
this unit when the two serine residues are phosphorylated, and it cannot
interact
with proteins containing a phosphorylation unit in which the serine residues
are
mutated to non-phosphorylatable amino acids. By interacting with the
phosphorylated proteins on this unit, the h-PTrCP protein controls their
ubiquitinylation and their targeting towards degradation by proteasome.
The virus protein Vpu and the cell proteins IxB and P-catenin may be
mentioned in particular among these proteins.
It has also been found that the h-PTrCP protein interacts via its F-box with
the Skplp protein, so it forms part of a novel SCF complex, SCF-h-PTrCP, which
selects certain cell or virus proteins for degradation by proteasome.
Through its activity of targeting towards proteasome degradation pathways,
the h-PTrCP protein according to the invention acts as cell mediator of the
Vpu
protein in cells infected with HIV-1 virus.
Without wishing to exclude other theories, it is thought that, in cells
infected with HIV-1 virus, the virus uses, via the Vpu protein, the SCF
complex (of
CA 02370098 2000-07-28
6
which the PTrCP protein forms part) to induce degradation of the CD4 receptor,
which will favor the replication of the virus and the release of the
infectious
virions.
The invention further relates to the peptide fragments of the h-OTrCP
protein which result from the addition, deletion and/or replacement of one or
more
amino acids, said peptide fragments having conserved the activity of
interacting
with proteins degradable by proteasome, particularly with the Vpu protein of
HIV-1 virus, with the cell protein IxB or the cell protein 0-catenin and/or
with the
Skplp protein.
The invention relates in particular to the peptide fragments which comprise
at least one of the following amino acid sequences of h-PTrCP:
251-569,
292-569,
292-396,
292-545 and
1-291.
Very particularly preferred peptide fragments are those which are partially
or totally devoid of the F-box or those which are partially or totally devoid
of the
WD units.
One particularly preferred peptide fragment is the mutant with residues 32-
179 deleted, which is hereafter called PTrCPOF.
The present invention further relates to the nucleic acid sequences, namely
the genomic DNA sequences and the cDNA or mRNA sequences, which comprise
or consist of a concatenation of nucleotides coding for the h-PTrCP protein or
for
any one of its peptide fragments as defined above.
The invention relates notably to those nucleic acid sequences coding for the
h-PTrCP protein and its peptide fragments described above which are
represented
by:
a) the cDNA sequence SEQ ID No. 1 coding for said h-PTrCP protein and the
cDNA sequences of the nucleic acid fragments coding for said peptide
fragments;
b) the DNA sequences which hybridize with the above sequences under strict
conditions;
c) the DNA sequences which, due to the degeneracy of the genetic code, result
from the sequences a) and b) above and code for the h-OTrCP protein or its
CA 02370098 2000-07-28
7
fragments; and
d) the corresponding mRNA and DNA sequences.
The proteins and peptide fragments according to the invention can be
obtained by the genetic engineering technique comprising the following steps:
- culture of a microorganism or eukaryotic cells which have been transformed
with
the aid of a nucleic acid sequence according to the invention; and
- recovery of the protein or the peptide fragment produced by said
microorganism
or said eukaryotic cells.
This technique is well known to those skilled in the art. Further details on
this subject may be obtained by reference to the following work: Recombinant
DNA Technology 1, Editors Ales Prokop, Raskesh K. Bajpai; Annals of the New
York Academy of Sciences, volume 646, 1991.
They can also be prepared by the conventional peptide syntheses well
known to those skilled in the art.
The nucleic acids according to the invention can be prepared by chemical
synthesis and genetic engineering using the techniques well known to those
skilled
in the art, as described e.g. by SAMBROOK et al. (supra).
For example, the cDNA sequences according to the invention can be
synthesized by amplifying the mRNAs of human cells by the PCR (Polymerase
Chain Reaction) method, as described e.g. by GOBLET et al. (Nucleic Acid
Research, 17, 2144, 1989), using, as primers, synthetic oligonucleotides
defined
from the DNA sequence SEQ ID No. 1.
The amplified nucleic acid fragment can then be cloned by the techniques
described by AUSUBEL et al. (Current Protocols in Molecular Biology, chapter
3,
supra).
The invention further relates to transgenic animals which express a
transgene for the h-OTrCP protein of the invention, or transgenic animals in
which
the PTrCP gene has been invalidated.
These transgenic animals or animals in which the h-PTrCP protein gene has
been invalidated may be used as models for the in vivo study of perturbation
of the
cell cycle and proliferation by the absence or overexpression of the gene for
the h-
PTrCP protein or for truncated or mutated forms of this protein, the Skplp
protein,
the Vpu protein, the IxB protein or the P-catenin protein.
These transgenic animals are obtained by techniques well known to those
skilled in the art, such as those described in Manipulating the mouse embryo;
a
CA 02370098 2000-07-28
8
laboratory manual. HOGAN B., BEDDINGTON R., COSTANTINI F. & LACY
E., Cold Spring Harbor laboratory press, second edition, 1994.
The preferred animals are mammals such as mice or rats.
The invention further relates to the prokaryotic microorganisms and
eukaryotic cells transformed with the aid of an expression vector containing a
DNA
sequence according to the invention. This expression vector, which can be e.g.
in
the form of a plasmid, must contain, in addition to the DNA sequence of the
invention, the means necessary for its expression, such as, in particular, a
promoter,
a transcription terminator, an origin of replication and, preferably, a
selection
marker. The transformation of microorganisms and eukaryotic cells is a
technique
well known to those skilled in the art, who will easily be able to determine,
as a
function of the microorganism to be transformed, the means necessary for the
expression of the DNA sequence according to the invention.
The preferred microorganism for the purposes of the invention is E. coli,
while the yeast used is preferably Saccharomyces cerevisiae.
COS, CHO, SF9, Jurkat and other cells, all of which are listed in the
ATCC, may be mentioned in particular as examples of eukaryotic cells which are
suitable for the purposes of the invention.
The invention further relates to the eukaryotic cells cotransformed with
expression vectors containing on the one hand the DNA sequence coding for the
Vpu protein, for the Skplp protein, for the IxB protein or for the mutated P-
catenin
proteins, and on the other hand a sequence coding for the h-OTrCP protein,
said
expression vectors also containing means useful for their expression,
including in
the yeast two-hybrid system.
The present invention therefore further relates to the anti-HIV-1 antiviral
agents consisting of the peptide fragments of the h-PTrCP protein of the
invention
which have conserved the properties of interaction of the h-PTrCP protein
either
with the Vpu protein or with the Skpip protein. These peptide fragments are
devoid of the F-box or the WD units, so they are no longer able to interact
with the
Skpip protein or, respectively, the Vpu protein.
Other antiviral agents, antitumoral agents or anti-inflammatory agents
which may be mentioned are antibodies directed against the h-PTrCP protein of
the
invention and its peptide fragments, said antibodies being a further subject
of the
invention.
These antibodies can be monoclonal antibodies obtained by the well-known
CA 02370098 2000-07-28
9
method of KOHLER and MILSTEIN (Nature, 256, 495-497, 1975) or polyclonal
antibodies obtained by the conventional methods of animal immunization
(Antibodies, a laboratory manual. E. Harlow & D. Lane. Cold Spring Harbor
laboratory press, 1988).
Finally, antiviral agents, antitumoral agents or anti-inflammatory agents
which may be mentioned are antisense oligonucleotides which block the
transcription or translation of the h-ATrCP protein of the invention and which
hybridize with a nucleic acid sequence as defined above, said oligonucleotides
also
forming a further subject of the present invention.
These antisense oligonucleotides are prepared by techniques well known to
those skilled in the art, such as those described by AUSUBEL et al. (Current
Protocols in Molecular Biology, Green Publishing Associates and Wiley-
Interscience, New York, 1989, published up to 1997).
The peptide fragments of h-OTrCP which possess the F-box or which have
conserved both the WD units and the F-box can be used as antitumoral or anti-
inflammatory agents.
The peptide fragments of h-OTrCP which are devoid of the F-box can be
used in gene therapy for the treatment of osteoarticular inflammatory diseases
or
acute inflammatory syndromes which are accompanied by NFxB activation
induced by the massive release of TNFa during these processes.
As illustrated in Figure 7, the expression of h-PTrCPOF is capable of
massively inhibiting, by a factor of about 20, the transcription activation
induced
by TNFa. Therefore, h-OTrCPOF could act as a potent anti-inflammatory agent in
any pathological condition associated with an intense inflammatory reaction
due to
a release of TNFa. For example, several attempts are currently being made to
apply gene therapy to rheumatoid polyarthritis by injecting recombinant
viruses
into the damaged joints. Vectors expressing h-OTrCPOF can be used in these
gene
therapy experiments on inflammatory syndromes. These vectors may be of several
types (retroviruses, adenoviruses; ANDERSON F., Nature, 392, 25-30, 1998). The
expression of h-ATrCPOF may be monitored by its effects on the inhibition of
NFxB activation by TNF.
The present invention further relates to the use of the h-OTrCP protein, or
the nucleic acid sequences coding for this protein or for its peptide
fragments, for
the screening of therapeutic agents which are capable of modulating the
interaction
of the h-OTrCP protein with proteins degradable by proteasome, and
particularly
CA 02370098 2000-07-28
for the screening of:
= anti-HIV-1 antiviral agents capable of inhibiting the interaction between
the h-
PTrCP protein and the Vpu protein and/or inhibiting the interaction between
the h-OTrCP protein and the Skplp protein;
5 = antitumoral agents capable of perturbing the regulation of the cell cycle
or the
protein degradation processes in tumoral human cells by modulating (inhibiting
or activating) the interaction between the h-OTrCP protein and the Skplp
protein, and by reactivating the interaction between the h-PTrCP protein and
the mutated 0-catenin proteins in tumoral cells, or between the PTrCP protein
10 and the normal 0-catenin protein in tumoral cells devoid of the APC
protein;
= anti-inflammatory agents capable of perturbing the activation of the NFxB
transcription factor by inhibiting the interaction between the h-PTrCP protein
and the IKB protein; and
= anti-Alzheimer agents capable of reducing the degree of degradation of
catenin in neuronal cells by inhibiting the interaction between the h-PTrCP
protein and the 0-catenin protein.
In fact, by perturbing the Vpu/h-OTrCP and/or Skplp/h-PTrCP interactions,
it is possible:
- either to inhibit the replication and production of HIV-1 virus by infected
cells;
- or to inhibit the entry of the cell cycle into the S phase and to have an
antiproliferative effect.
By perturbing the IKB/h-PTrCP and/or Skp1p/h-PTrCP interactions, it is
possible to inhibit the degradation of the IKB protein by proteasome and hence
to
inhibit the activation of the NFKB transcription factor.
Finally, by activating the mutated P-catenin/h-PTrCP interaction, it is
possible to activate the degradation of the P-catenin which has accumulated in
tumoral cells. By inhibiting the P-catenin/h-PTrCP interaction in patients
suffering
from Alzheimer's disease, it is possible to reduce the apoptosis of neuronal
cells.
Screening, of modulators of the h-5TrCP/protein interaction
The antiviral agents can be selected either from random peptide banks on
the surface of phages (SCOTT J. et al., Science, 249, 386-390, 1990) or by
using
random synthetic oligonucleotides according to the technique of the SELEX type
(TUERK and GOLD, Science, 249, 505-510, 1990). This technique makes it
CA 02370098 2000-07-28
11
possible to isolate, from a very large pool of oligonucleotides, those which
have a
high affinity for the protein of interest, namely the h-OTrCP protein in the
present
case. They are called aptamers. From these aptamers it will be possible, using
the
screening method below, to select those which inhibit both the Vpu/h-OTrCP and
Skp1p/h-PTrCP interactions.
The screening method defined above can be carried out e.g. by using the
yeast two-hybrid system in which yeast cells co-expressing the h-PTrCP protein
according to the invention and one of the proteins Vpu, IxB, P-catenin or
Skplp
are cultivated on appropriate selective media in the presence of the test
substance;
the selective media are the media commonly used in this field and hence are
well
known to those skilled in the art.
The yeast two-hybrid system is described by FIELDS and SONG in Nature,
340, 245-246, 1989, and in patent US 5 667 973. This two-hybrid system is
based
on detection of the protein-protein interactions by activation of the His or
LacZ
reporter gene under the control of Ga14 transcription activation domains in
the
yeast.
In this two-hybrid system, a yeast is cotransformed with a two-hybrid
vector containing the cDNA of one of the proteins and a vector containing the
cDNA of the other protein, each of said vectors containing either a DNA
binding
domain or a transcription activation domain. The two proteins are then
expressed
by the yeast in an appropriate culture medium, for example a histidine-free
culture
medium. The interaction between the two hybrid proteins allows on the one hand
activation of the His3 gene and growth of the yeasts on a histidine-free
medium, as
well as activation of the LacZ gene, which is disclosed by a color reaction
specific
for 0-galactosidase. It is therefore possible to verify the interaction when
the yeasts
grow on a histidine-free medium and when a color reaction is observed.
A further possibility is to use the halo test as described by Valtz & Peter
(Meth. Enzymol., 283, 350-365, 1997) to detect whether there is any
interaction.
It is also possible to use variants of the two-hybrid system, such as the
three-hybrid system described by TIRODE et al. (J. Biol. Chem., 272, 22995-
22999, 1997) or by COLAS et al. (Nature, 380, 548-550, 1996), in which a
peptide
inhibiting the interaction can be expressed as a third partner to inhibit the
interaction of the other two. A random peptide bank can also be used in this
way.
A further possibility is to use the reverse-hybrid system described by
VIDAL et al. (Proc. Natl. Acad. Sci., 93, 10315-10320), in which selection is
CA 02370098 2000-07-28
12
carried out against an interaction and not for an interaction. In this system,
as in
the conventional two-hybrid svstem, it is possible to screen banks of small
chemical molecules, including those derived from chemical synthesis, in order
to
bring yeasts cotransformed with two-hybrid or reverse-hybrid vectors carrying
fusions with the Vpu protein. he IxB protein, P-catenin, the h-(3TrCP protein
or
the Skplp protein into conta~, with these small molecules in the search for an
inhibitor of the Vpu/h-PTrCP, Skp1p/h-OTrCP, P-catenin/h-PTrCP or IxB/h-
(3TrCP interactions.
The screening assays for interaction inhibitors may also be carried out using
the conjugative two-hybrid system (FROMONT-RACINE et al., Nature Genetics,
16, 277-282, 1997), the membrane two-hybrid system (BRODER Y.C. et al., Curr.
Biol., 8, 1121-1124, 1998) and optionally, if phosphorylations can take place
in the
bacteria, the bacterial two-hybrid system (KARIMOVA et al., Proc. Nati. Acad.
Sci., 95, 5752-5756, 1998).
This screening can also be effected in vitro by using one of the proteins
Vpu, IxB, P-catenin or Skplp and the h-PTrCP protein, one of the proteins
being
immobilized on an appropriate support and the other being labeled by any means
used in the methods of detecting biological substances, it being possible for
this
labeling means to be e.g. a radioactive isotope, a luminescent agent, biotin
or a
specific antibody.
One of the proteins will preferably be immobilized in the form of a fusion
protein with glutathione S-transferase (GST) on agarose-glutathione beads or
in
microtiter plates, the GST serving as an agent for coupling said protein with
the
beads or with the wells of the plates.
This can be done particularly using the scintillation proximity assay (SPA)
described by BOSWORTH et al. (Nature, 341, 167-168, 1989) and marketed by
Amersham. This assay consists in labeling one of the proteins with a
radioactive
element, for example tritium, and immobilizing the other protein on magnetic
beads or agarose-glutathione beads. The inhibitory effect of the test
substances on
interactions involving the h-OTrCP protein can easily be detected, without
separation of the bound or free radioactive species, according to the
protocols
described by BOSWORTH et al. (supra).
Another possible technique is that of surface plasmon resonances described
by KARLSSON et al. (J. Immunol. Methods, 145, 229-233, 1991), using Biacore,
marketed by Pharmacia, to isolate the inhibitors of interactions involving the
h-
CA 02370098 2000-07-28
13
PTrCP protein according to the invention.
The inhibitory activity of the antiviral agents selected in this way may be
verified by assays on CD4+ T cells or on chimpanzees infected with HIV-1 virus
or
SIV Cpz.
The antitumoral agents and anti-inflammatory agents - ligands of the
h-OTrCP protein of the invention - can also be isolated by the two-hybrid
techniques or related techniques or by interaction in vitro with combinatorial
banks
of peptides or other chemical products, as described above.
The specificity of the antiviral, antitumoral or anti-inflammatory agents
selected by the two-hybrid assay can then be determined by the culture of
mammalian cells, for example human cells transfected with the OTrCP protein or
a
fragment thereof, in the presence of a reporter gene specific for the protein
involved in the pathological condition which it is desired to treat.
Thus, for the IxB protein, it will be possible to use human cells originating
from the cell lines Hela, 293, 293T, etc. and the reporter gene dependent on
NFKB
sites (3Enh-xB-ConA Luc), which controls the expression of luciferase.
In non-stimulated human cells, the human PTrCP protein is transitorily
expressed from a eukaryotic expression vector such as pCDNA3 (Invitrogen), or
any other eukaryotic expression vector, which has inserted the DNA coding for
the
PTrCP protein under the control of a strong promoter of the cytomegalovirus,
CMV, or the like. An amount of the order of 3 g of this vector permitting the
expression of the PTrCP protein will be cotransfected by one of the common
transfection techniques (calcium phosphate, lipofectamine (Life Technologies),
electroporation (Ausubel and Sambrook, cf. below) etc.) with 1 g of a
reporter
vector dependent on NFxB sites (3Enh-KB-ConA luc) or independent of NFxB
sites (RSV Luc or ConA Luc) which control the expression of the luciferase
reporter gene. Molecules capable of inhibiting the h-PTrCP/IIcB interaction
will
inhibit the increase in the expression of luciferase in this assay. These
inhibitors
will be added to the culture medium for at least 6 hours, 24, 36 or 48 hours
after
transfection. The specificity of these inhibitors may be checked by verifying
that
they have no effect on RSV Luc or ConA Luc. Another possible alternative will
be
to use the dual luciferase system from Promega, in which two different
reporter
vectors can be assayed at the same time.
According to one experimental protocol similar to that described above, but
with stimulated cells, it will be possible to verify that the inhibition
induced by the
CA 02370098 2000-07-28
14
expression of the h-PTrCPOF fragment on the TNF-dependent transcription
activation has been nullified.
Thus, in this second assay, the human cells are cotransfected with 1 g of
reporter vector, i.e. either 3Enh-xB-ConA Luc, ConA Luc or RSV Luc, and with 3
g of pCDNA3 expressing the h-PTrCPOF peptide fragment, which is a mutant of
(iTrCP with its F-box deleted. 24 to 48 h after transfection, the cells are
treated for
6 h with TNF or okadaic acid (OKA), which are potent NFxB activators
(BAUERLE et al., Cell, 1996, 87, 13-20). The h-PTrCPOF mutant has a massive
inhibitory effect on the expression of the luciferase reporter compared with a
control plasmid transfected under the same conditions. This effect is due to
the
inhibition of IxB degradation induced by the binding of the h-PTrCPAF mutant
in
place of the endogenous wild-type h-PTrCP protein. Therefore an inhibitor of
the
h-PTrCP/IKB interaction will also inhibit the h-PTrCPOF/IxB interaction and
hence will reverse the inhibitory effect of the h-PTrCPOF fragment. The
potential
inhibitors are added to the medium under the same conditions as those
indicated
above. From the cells stimulated with TNF or OKA, those inhibitors are chosen
which induce an increase in the expression of the reporter gene.
After the selection of inhibitors in the previous two assays, a third assay
can
be carried out to verify that they are capable of inhibiting the activation of
NFxB
induced by stimulation of the cells with TNF or OKA.
The cells transfected only with 1 g of reporter vector (3Enh-KB-
ConA Luc) and stimulated for 6 h with TNF or OKA are treated with the
potential
inhibitors. To be specific, these inhibitors must have an effect only on the
IKB-
dependent reporter vectors and not on the other reporter vectors (ConA or
RSV).
In the case of P-catenin, it will be possible to use human cells originating
from the above lines transformed with mutated P-catenin or the peptide
fragment
of PTrCP devoid of the F-box, in the presence of vector Top-TK-Luci, which
contains a multimer of TCF-LEF sites responding to P-catenin, or Fop-tk Luci,
which contains an inactive mutated multimer and no longer responds to P-
catenin.
Detection of P-catenin mutations
Furthermore, as oncogenic mutated P-catenin can easily be distinguished
from wild-type P-catenin by the fact that the former, in contrast to the
latter, is
incapable of binding to PTrCP in the two-hybrid assay, P-catenin mutations can
be
detected in human tumors by measuring the interaction with PTrCP in the two-
CA 02370098 2000-07-28
hybrid assay.
This assay is valuable because P-catenin mutations are found in numerous
cancers such as colon cancer, melanomas, hepatocarcinomas, etc. The only way
of
detecting these mutations hitherto was to sequence the P-catenin by carrying
out
5 RT-PCR on the RNA of the tumors studied. For greater reliability, several
double-
stranded sequences have to be made in this assay of the prior art. Also, the
existence of a mutation does not in itself indicate the oncogenic character of
this
mutation. It could be a case of polymorphism unconnected with tumorigenicity.
The advantage of the two-hybrid assay with the PTrCP protein is that, in
10 times equivalent to those required to obtain a sequence, it is possible to
obtain a
clear answer regarding the percentage of oncogenic mutated P-catenin sequences
detected from the tumoral RNA. Over a large number of colonies, the percentage
of oncogenic forms of P-catenin which are incapable of interacting with PTrCP,
compared with the wild-type forms which do interact with PTrCP, can be
15 determined precisely. The assay can be performed in a time equivalent to
that
required to obtain a few sequences, and at a reduced cost.
This assay comprises the following steps:
1- Preparation of the total RNA from a biopsy of a tumor and of the
surrounding
healthy tissue, as control, using one of the various RNA preparation
techniques or
kits (AUSUBEL et al., Current Protocols in Molecular Biology).
2- Amplification of the P-catenin sequences of the tumor and of the
surrounding
healthy tissue by carrying out RT-PCR on the RNA samples using a pair of
oligonucleotides which permit amplification either of the N-terminal part only
(1-
130), which contains the most frequently encountered oncogenic mutations
(RUBINFELD B. et al., Science, 275, 1790-1792, 1997; DE LA COSTE et al.,
Proc. Natl. Acad. Sci. USA, 95, 8847-8851, 1998), or of the whole of the P-
catenin
coding sequence.
3- Insertion of these amplified fragments, by ligation, into one of the two-
hybrid
vectors, for example pGAD1318, to give a frame fusion with the Ga14
transcription
activation domain or the equivalent activation domain for transcription or
binding
to the DNA coded for by the two-hybrid vector used.
4- Transformation of bacteria of various appropriate strains and plating of
the
whole of the transformant on LB-ampicillin medium.
5- Harvesting of all the colonies and plasmid minipreparation (AUSUBEL,
supra).
6- L40 yeasts or any other appropriate strain of yeast will be cotransformed
by the
CA 02370098 2000-07-28
16
plasmid containing the P-catenin sequences of the above minipreparation with a
fusion hybrid containing PTrCP, for example pLexA-ATrCP, in which the PTrCP
is fused to the LexA DNA binding domain. A two-hybrid assay is performed on
all
the colonies obtained, for example by plating the cotransformed yeasts on DO-W-
L
medium and then transferring the colonies to selective medium for detection of
the
interactions, i.e. DO-W-L-H medium, or in the presence of X-Gal for detection
of
the interactions by P-galactosidase production (BARTEL P. & FIELDS S., Meth.
Enzymol., 254, 241-263, 1995).
This assay requires the following reagents:
1- Vector pGAD1318 predigested at the appropriate sites for inserting the
amplified fragment obtained by RT-PCR.
2- The appropriate oligonucleotides for amplifying the P-catenin sequence and
then
inserting the amplified P-catenin sequences. The oligonucleotide primers for
amplification will be chosen according to the mode of insertion of the
amplified
fragment and the chosen sites.
3- Plasmid pBTM116-PTrCP expressing PTrCP fused to the LexA DNA binding
domain.
4- As control, plasmids coding for fusion hybrids with control proteins, for
example pLexRas and pGAD1318Raf.
The gap repair technique (SCHWARTZ H. et al., Mutation detection by a
two-hybrid assay, Hum. Mol. Gen., 7, 1029-1032, 1998) may also be applied for
this assay in order to insert the sequence of the amplified P-catenin fragment
into
the two-hybrid vector and transform yeasts directly without proceeding via the
step
of prior transformation in bacteria.
The invention will now be described in detail with the aid of the following
.:ccount of experiments.
A large part of the techniques described in these Examples, which are well
known to those skilled in the art, is explained in detail in the book by
SAMBROOK et al. (supra) or in the book by AUSUBEL et al. (supra).
The following description will be understood more clearly with the aid of
Figures 1 to 12, in which:
- Figure 1A is a photograph of a Petri dish showing the growth of yeast
cells cotransformed by plasmids containing Vpu,, + VBP1, Vpu, + h-PTrCP,
VpW_2/6 + h-PTrCP, VpW, h-PTrCP + Vpw and h-PTrCP + CD4, on medium in
the presence of histidine (His+), on medium in the absence of histidine (His-)
and
CA 02370098 2000-07-28
17
on medium in the presence of the 0-galactosidase substrate X-Gal (P-Gal);
- Figure 1B is a photograph of a gel (Northern blot) showing 3 mRNAs of
the h-PTrCP protein of the invention;
- Figure 1C is a photograph of an immunoblot showing the expression of
the h-PTrCP protein of the invention;
- Figure 2 shows the sequences of 4 proteins: h-PTrCP of the invention,
PTrCP1 of Xenopus, Met30p of Saccharomyces cerevisiae and Scon2p of
Neurospora crassa;
- Figure 3 is a photograph of a 15% SDS-PAGE gel showing the interaction
between Vpu,, and the h-(3TrCP protein of the invention, produced in vitro;
- Figure 4 is a photograph of a Petri dish showing the growth of yeast cells
cotransformed by plasmids containing Skplp + h-PTrCP; Skplp + h-PTrCP-07W,
Skplp + VBP1 and Skplp + CD4., on medium in the presence of histidine (His+),
on medium in the absence of histidine (His-) and on medium in the presence of
the
(3-galactosidase substrate X-Gal (P-Gal);
- Figure 5 is a schematic representation of the degradation of the CD4
receptor induced by the Vpu protein, showing the network of interactions
described
above;
- Figure 6 is a photograph of a Petri dish showing the growth of yeast cells
cotransformed by plasmids containing PTrCP + IxBa, PTrCP + IxBa S32-36AA,
PTrCP + Raf, Ras + IxBa, PTrCP + Vpuc and Ras + Raf, on His+ medium, on
His- medium and the expression of P-Gal;
- Figure 7 is a graphic representation showing the expression of luciferase
(in light units per g: RLU/ g protein) in cells transfected with the
constructs
h-PTrCP and h-PTrCPOF and the control plasmids and the following reporter
vectors: 3Enh-KB-ConA luc, ConA luc, RSV luc;
- Figure 8 is a photograph of an immunoblot showing the detection of the
phosphorylated or non-phosphorylated IxB protein and the h-PTrCP protein or
the
h-PTrCPOF fragment, in the presence of anti-IxBa, anti-IxBa-S32 and anti-Myc
antibodies;
- Figure 9 is a photograph of an immunoblot showing the detection of the
phosphorylated or non-phosphorylated IxB protein with the h-PTrCP protein or
the
h-(iTrCPOF fragment, in the presence of anti-IxBa-S32 and anti-IxBa
antibodies;
- Figure 10 is a photograph of a Petri dish showing the growth of yeast cells
cotransformed by plasmids containing PTrCP +PCatly130, PTrCP +
CA 02370098 2000-07-28
18
PCati_.13o S33-37AA, PTrCP2 + PCati_.130, PTrCP2 + PCati-130 S33-37AA and
PTrCP +PCat, on His+ medium, on His- medium and the expression of P-Gal;
- Figure 11 is a graphic representation showing the expression of luciferase
(RLU/ g protein) in cells transfected with plasmid pcDNA3 and plasmids
containing PCatON, PTrCP, (3TrCPOF, KIA 696 (PTrCP2) and KIA 696 AF
(PTrCP20F);
- Figure 12 is a photograph of an immunoblot showing a study of the
stability of the P-catenin protein detected with anti-pCat antibodies under
the
influence of the expression of the h-PTrCP protein or the h-PTrCPOF fragment
detected by the anti-Myc antibody.
Example 1: Yeast two-hybrid screening / identification of the cDNA sequence of
the h&TrCP protein, and the h- TrCP protein
The chosen target was the cytoplasmic domain of the Vpu protein. Amino
acid residues 28 to 81 of the Vpu protein from the LAI isolate of HIV-1 were
fused
to the Ga14 DNA binding domain (Ga14BD). The cDNA library screened was that
of Jurkat cells (human T lymphocyte line, ATCC no. TIB 152) and it was fused
to
the Ga14 activation domain (Ga14AD) in vector pGAD1318 (BENICHOU et al., J.
Biol. Chem., 269, 30073-30076, 1994).
The 1.3 kb clone which was initially isolated by the two-hybrid system
(called VBP1) codes for a partial complementary DNA. This partial cDNA codes
for a 319 amino acid fragment corresponding to the C-terminal domain of the h-
PTrCP protein. It contains seven repeating units followed by a 24 amino acid C-
terminal tail. These repeating units, which are known, are called WD units
because
their end usually terminates in the sequence Trp-Asp (WD). It will be noted
that
WD units are involved in protein-protein interactions (NEER et al., Nature,
371,
297-300, 1994).
The clone isolated in this way was characterized by DNA sequencing on an
Applied Biosystems automated sequencer known as ABI 373A. The DNA
sequencing technique is well known to those skilled in the art and is
described
especially in the book by SAMBROOK et al. entitled "Molecular Cloning: a
Laboratory Manual", published by Cold Spring Harbor Press, NY, 1989.
A cDNA library search showed that this clone is homologous with a
sequence coding for the PTrCP protein of Xenope, previously identified by
SPEVAK et al. (Mol. Cell. Biol., 13, 4953-4966, 1993).
CA 02370098 2000-07-28
19
The complete cDNA (2.1 kb) of the h-OTrCP protein, which has SEQ ID
No. 1, was obtained by carrying out the polymerase chain reaction (PCR)
technique
on a plasmid preparation corresponding to the complementary DNA library of
Jurkat cells, as defined above, in vector pGAD1318.
In addition to the seven WD units identified in the C-terminal fragment, the
whole h-OTrCP protein according to the invention possesses an N-terminal
domain
of about 250 amino acids. The N-terminal fragment contains a unit for which a
consensus sequence has recently been defined by the term F-box and whose role
is
supposedly to target proteins towards the protein degradation machinery
mediated
by ubiquitin through the interaction of proteins containing this F-box with
the
Skplp protein (BAI et al., 1996, supra).
Thus, via its WD units, the h-OTrCP protein on the one hand is capable of
interacting with the Vpu protein and on the other hand possesses an F-box unit
which interacts with the Skplp protein and is therefore capable of targeting
proteins towards proteasome degradation pathways.
The h-OTrCP protein possesses 569 amino acids and comprises one F-box
and seven WD units having the following positions in the sequence SEQ ID No.
2:
- F-box: amino acids 147-191,
- first WD unit: amino acids 259-292,
- second WD unit: amino acids 304-332,
- third WD unit: amino acids 343-372,
- fourth WD unit: amino acids 387-415,
- fifth WD unit: amino acids 427-455,
- sixth WD unit: amino acids 467-492,
- seventh WD unit: amino acids 516-544.
The technique of sequence alignment according to MACAW's program
(SCHULER et al., Proteins: structure, function and genetics, 9, 180-190,
1991), a
technique well known to those skilled in the art, was used to determine
whether the
protein isolated in this way had any homology with already known proteins.
The results obtained are reported in Figure 2, which shows that the h-
PTrCP protein has a homology of:
= 88% with the x-OTrCP1 protein of Xenopus,
= 33% with the Met3Op protein of Saccharomyces cerevisiae, a transcription
inhibitor involved in biosynthesis, and
= 31% with the Scon2p protein of Neurospora crassa.
CA 02370098 2000-07-28
Figure 2 also shows the location of the F-box and the WD units.
Example 2: Cloning of the cDNA of the h-fiTrCP protein
The cDNA of the h-(3TrCP protein of SEQ ID No. 1 was amplified by
5 carrying out PCR on 2 g of plasmid DNA from the pGAD cDNA library using
two amplification turns, the outer pair of primers for the first turn
consisting of the
sense primer A of SEQ ID No. 3 (in pGAD1318) and the antisense primer B of
SEQ ID No. 4 (in VPB1) and the inner pair of primers for the second turn
consisting of the sense primer C of SEQ ID No. 5 (in pGAD1318) and the
10 antisense primer D of SEQ ID No. 6 (in VPB1).
Following this procedure, a 1.4 kb fragment, subcloned in plasmid pGAD-
VBP1 in the form of a 5'Spel-3'BglII fragment, was isolated to reconstitute
the
pGAD-h-OTrCP clone.
The sequences coding for VBP1 (amino acid residues 251 to 569 of the
15 h-PTrCP protein) or coding for the whole h-PTrCP protein were subcloned in
vectors pGBT9, pGEX4T2 (Phannacia) or pCDNA3 (only for the h-OTrCP
protein) (Invitrogen) using standard procedures.
Example 3: Specific interaction of the Vpuprotein with the h-gTrCP protein
20 The experimental results which demonstrate the specific interaction of the
novel human OTrCP protein with the Vpu protein are illustrated in Figure 1.
3a- Interaction between the Vpu protein and the h-OTrCP protein via the
two-hybrid screen described above
Figure 1A shows the interaction, via the two-hybrid technique, of the C-
terminal region of the h-OTrCP protein (VBP1) originating from the cDNA
library
of Jurkat cells (line 1), or the whole h-OTrCP protein (line 2), fused to the
Ga14
activation domain, with the Vpu cytoplasmic domain fused to the Ga14 DNA
binding domain, or vice-versa (line 5). The interaction is revealed by
activation of
the two reporter genes His3 and LacZ; the His3 gene permits the growth of
yeasts
in the absence of histidine (-His panel) and the LacZ gene induces the
production
of P-galactosidase, revealed by the blue coloration in the presence of the
substrate
X-Gal (0-Gal panel). This interaction is specific since it is not found
between the
Vpu protein and the vector alone (line 4) or between the h-OTrCP protein and
another protein such as the cytoplasmic region of CD4 (line 6). The +His panel
is
a control panel showing that all the combinations, including those where there
is no
CA 02370098 2000-07-28
21
interaction, grow in the presence of histidine.
It should be noted that the h-OTrCP protein does not interact with an
inactive Vpu protein mutant, Vpuc-2/6 (line 3), a clone mutated on the two
serine
residues Ser 52 and Ser 56, which are essential for the activity of Vpu
(MARGOTTIN et al., 1996, supra). This result demonstrates that there is a
correlation between the capacity of Vpu to interact with h-OTrCP and its
activity.
3b- Demonstration of the expression of the h- TrCP protein by Northern
blot analysis
By Northern blot analysis of the mRNAs of different human cell lines using
a 5' probe, it was found that several messenger RNAs (mRNAs) hybridize with a
probe corresponding to h-PTrCP (Fig. 1B). These mRNAs, of respective sizes
2.4 kb, 3.5 kb and 7 kb, are found in all the human tissues assayed. This
multiplicity of mRNAs is reminiscent of the situation described by HUDSON et
al.
(Dev. Genet., 19, 190-198, 1996) for the mRNAs of the PTrCP of Xenope, for
which 3 different mRNAs, with respective sizes similar to those found here for
the
mRNAs of h-PTrCP, were reported.
3c- Demonstration of the expression of the h-~TrCP protein by Immunoblot
analysis
Anti-h-OTrCP antipeptide antibodies (Abs) were produced in rabbits by
immunization with the synthetic peptide 275-293 corresponding to the first WD
unit of the h-OTrCP protein. These Abs were purified by the affinity method by
adsorption on 30 g of the GST-VBP1 fusion protein, which is expressed in E.
coli
from vector pGEX-VBP1 and immobilized after electroblotting on a
nitrocellulose
membrane. The purified Abs antibodies were then eluted with the eluent
glycine.HC1, pH 3.0, neutralized with 1 M TRIS buffer, pH 8.0, and used for
analysis, by the Western blot technique, of the expression of the h-PTrCP
protein
in human Sup Tl cells (Tl), in rabbit reticulocytes (RRL) and in canine
microsomal membrane lyzates (CMM).
Figure 1C shows the expression of the h-OTrCP protein detected in a lyzate
of human T cells of the Sup Tl line (line 1) and Promega rabbit reticulocytes
(line
3) by the Western blot technique using the previously obtained anti-h-OTrCP
antibodies directed against the peptide 275-293. On the other hand, no
proteins
corresponding to h-OTrCP could be detected in Promega canine pancreatic
microsomal membranes (line 2). The size of the h-OTrCP protein detected (60
kD)
indicates that the clone of h-PTrCP cDNA, which was characterized and is shown
CA 02370098 2000-07-28
22
in Figure 2, is capable of coding for the whole h-PTrCP protein.
Example 4: Mapping of the sites of interaction between Vpuc and the h-RTrCP
protein
The sites of interaction between the cytoplasmic domain of the Vpu protein
(Vpuc) and the h-ATrCP protein of the invention were determined as follows:
As regards Vpuc, it was shown that mutation of the serines in positions 52
and 56 (Vpuc-2/6 clone) totally eliminated the interaction between Vpu and h-
OTrCP.
As regards h-PTrCP, the results of two-hybrid interaction with the Vpu
cytoplasmic domain and the different mutants described below show that all the
WD units and the C-terminal tail are required for an optimum interaction, as
indicated in the Table below.
The following mutants are used:
- VBP1-AW, (VBP1 clone in which the first WD domain has been deleted;
residues 292 to 569, which correspond to a BglII.-Xhol fragment of VBP1);
= VBP1-OW4-7 (VBP1 clone in which WD domains 4 to 7 have been deleted;
residues 292 to 396); and
= VBPI-OC-ter (VBP1 clone in which the C-terminal tail after the 7th WD domain
has been deleted; residues 292 to 545)
by PCR using respectively the sense primer C, described above, and the
following
antisense primers E and F in VBP1:
primer E: SEQ ID No. 7
primer F: SEQ ID No. 8
The h-PTrCP-07W mutant (h-PTrCP clone in which the seven WD
domains have been deleted; residues 1 to 291) was constructed by inserting an
Spel-BglII fragment from the h-PTrCP protein into vector pGAD1318, and the
OTrCPOF mutant (deleted residues: 32 to 179) was obtained by deleting the
AvrII-
Asp718 fragment of the h-PTrCP protein with conservation of the reading frame.
The following method was used to verify that the interaction between the
Vpu and h-PTrCP proteins could take place in vitro: the two proteins were
introduced into rabbit reticulocyte lyzate (RRL). The Vpu/pTrCP complexes
formed in vitro were identified by co-immunoprecipitation using anti-h-OTrCP
antibodies directed against the peptide 553-569, which were prepared by the
same
method as that used to obtain the anti-h-PTrCP antibodies directed against the
CA 02370098 2000-07-28
23
peptide 275-293.
Figure 3 illustrates the interaction between the Vpu and h-OTrCP proteins
in vitro. Line 1 shows that the Vpu protein is not recognized by the anti-h-
PTrCP
antiserum, whereas line 5 shows that it precipitates in the presence of an
anti-Vpu
antiserum. Line 2 shows that the anti-h-PTrCP antibodies are capable of
coprecipitating the Vpu protein cotranslated in vitro with the h-PTrCP
protein.
Line 4 shows that the double mutant of Vpu mutated in positions Ser52 and
Ser56,
which is incapable of inducing CD4 degradation, does not interact with the h-
PTrCP protein and is not therefore coprecipitated by anti-h-PTrCP antibodies,
whereas lines 6 and 7 show that this mutant, Vpu,_2/6, is translated with the
same
efficacy as the Vpu protein.
CA 02370098 2000-07-28
24
U
.,+
~ + + O
+ +
U
~
NN
W
V W V
tn W)
F'' M M M M M
~ N N N cy N
4-4
0
I I
w w
.~ I I
~
U d d a U
H a a a. a h
~ > > > ~
CA 02370098 2000-07-28
Example 5: Interaction between the h-OTrCP protein and the Skplp protein
To demonstrate that the F-box unit was indeed functional and could
therefore effectively be used for targeting towards proteasome via the Skplp
protein, a two-hybrid assay was performed between the N-terminal domain of the
5 h-PTrCP protein and the Skplp protein, making it possible to reveal an
interaction
between the h-PTrCP protein and the Skplp protein.
The human Skplp protein described by BAI et al. (1996, supra) was
subcloned into vector pLexlO for analysis of the interaction with the h-PTrCP
protein in the yeast strain L40 (VOJTEK et al., Cell, 74, 205-214, 1993).
10 Figure 4 illustrates the results obtained. Line 1 of Figure 4 shows first
of all
that the h-PTrCP protein interacts with the Skplp protein. Line 2 shows that
the
N-terminal domain is sufficient to obtain the interaction, whereas line 3
shows that
the absence of the N-terminal domain of the h-(3TrCP protein in VBP1 removes
all
interaction with the Skplp protein. These results are important additional
15 arguments in favor of a role of the h-PTrCP protein in degradation of the
CD4
receptor mediated by the Vpu protein, and also corroborate the results of
FUJITA
et al. (1997, supra) and SCHUBERT et al. (1997, supra), showing that
degradation
of the CD4 receptor induced by the Vpu protein ought to take place in
proteasome.
It should be noted that the CD4 cytoplasmic domain is incapable of binding
20 directly to the Skplp protein (line 4).
Example 6: Model of the network of interactions involved in degradation of the
CD4 receptor
Degradation of the CD4 receptor induced by the Vpu protein is effected by
25 the network of interactions a) between the Vpu protein and the CD4
receptor,
b) between the Vpu protein and the WD units of the h-PTrCP protein, and c)
between the F-box of the h-PTrCP protein and the Skplp protein, this last
interaction allowing d) the targeting of the Vpu/CD4 complex towards
proteasome.
This network of interactions is illustrated schematically in Figure 5.
It is by way of such a network of interactions that degradation of the CD4
receptor by proteasome via the Vpu protein is caused.
Degradation of the CD4 receptor allows the release of the Gp160 envelope
protein and hence the release of infectious HIV-1.
One of the means of preventing the development of HIV-1 in the affected
patient therefore consists in preventing degradation of the CD4 receptor. One
of
CA 02370098 2000-07-28
26
the means of preventing this degradation in the light of the above degradation
process consists in looking for inhibitors, or anti-HIV antiviral agents,
which
inhibit the interaction either between the Vpu protein and the h-PTrCP
protein, or
between the h-PTrCP protein and the Skplp protein, by the processes described
above.
Example 7: Interaction between the h-OTrCP protein and the IxB protein
For this yeast two-hybrid assay, the proteins described below were fused
either to the Ga14 transcription activation domain (Gal4AD) or to the LexA DNA
binding domain:
-PTrCP = human OTrCP protein of the present invention,
- IKBa,
- IKBa S32-36A = IxBa mutant at serines S32 and S36 so that there is no
phosphorylation,
- Ras = control protein,
- Raf = control protein,
- Vpuc = cytoplasmic Vpu protein as described above.
The experimental results which demonstrate the specific interaction of the
novel human PTrCP protein with the IxB protein are illustrated in Figure 6.
This two-hybrid assay shows that:
- the two proteins h-PTrCP and IxB are capable of interacting,
- the h-OTrCP/IKB interaction is specific for the two hybrids since, when
one of the two hybrids is replaced by a hybrid with another protein, such as
Ga14AD-Raf or LexABD-Ras, there is no longer any interaction, whereas these
two
control hybrids are capable of interacting, and
- this interaction is removed when serine residues S32 and S36 of the IxB
protein are mutated to non-phosphorylatable residues like alanine.
An interaction between the Vpu protein of HIV-1 and the h-PTrCP protein
was also observed in this assay.
Example 8: IxB/h-RTrCP interaction in human cells: modulation of the
transcription activation of reporter izenes for NFKB activity by expression of
the
h-RTrCP protein or its h&TrCPOF fragment
In non-stimulated cells (NS) of the 293 cell line, the human PTrCP protein
or the h-PTrCPOF fragment is transitorily expressed from a eukaryotic
expression
CA 02370098 2000-07-28
27
vector such as pCDNA3 (Invitrogen), following insertion of the cDNA coding for
the h-OTrCP protein under the control of a strong cytomegalovirus promoter
(CMV). An amount of 3 g of this plasmid permitting expression of the h-OTrCP
protein or the h-OTrCPOF fragment is cotransfected by lipofectamine (Life
Technologies) with 1 g of a reporter vector dependent on NFxB sites (3Enh-xB-
ConA Luc) or independent of NFxB sites (RSV Luc or ConA Luc) which control
the expression of the luciferase reporter gene.
The results obtained (Figure 7) show that the h-ATrCPOF fragment is
capable of acting as a negative transdominant. By competing with the
endogenous
PTrCP, the h-PTrCPOF fragment inhibits the activation of NFxB induced by TNF
or okadaic acid (OKA). This activation of NFxB is measured by the activity of
a
reporter gene under the control of a promoter which has three NFKB binding
sites
(3Enh-xB-ConA Luc) (Arenzana et al., 1993, J. Virol., 67, 6596-6609). On the
other hand, the h-PTrCP protein has an activatory effect on the activation of
NFKB.
The h-PTrCP protein or the h-PTrCPAF fragment has no effect on the
transcription
of a reporter gene directed by a promoter which does not contain NFxB sites
(RSV Luc) (Invitrogen).
Example 9: Use of specific antibodies for revealing the interaction between
the h-
OTrCP protein and the endogenous IxB protein of 293 or Hela cells, and its
consequences on the stability of the IxB protein
The stability of the phosphorylated forms of IxB was analyzed in 293 cells
transfected by a control plasmid, by a pcDNA plasmid (Invitrogen) expressing
the
h-PTrCP protein, or by a pcDNA plasmid expressing the h-OTrCPOF fragment, the
h-PTrCP protein and the h-PTrCPOF fragment having been fused to the myc
epitope at the C-terminal end of this pcDNA vector. After 36 hours, the 293
cells
were stimulated with TNF in the presence of 100 g/ml of cycloheximide
(protein
synthesis inhibitor). The cytoplasmic proteins were separated on denaturing
polyacrylamide gel/SDS and then transferred to a nitrocellulose membrane and
incubated either with the 10B monoclonal antibody directed against the amino-
terminal part of IxB and recognizing all forms of the protein (a-IKBa; JAFFRAY
et al., Mol. Cell. Biol., 15, 2166-2172, 1995), or with a polyclonal antibody
specifically recognizing the phosphorylated forms of IxB (a-IxBa-S32 ; 9241S,
New England Biolabs), or with an anti-myc monoclonal antibody directed against
the myc epitope fused to h-PTrCP and h-PTrCPAF and showing the expression of
CA 02370098 2000-07-28
28
the latters in the transfected cells (a-Myc; SC40AC, Santa Cruz), by carrying
out a
Western blot (WB).
The results obtained (Figure 8) show that the expression of the h-OTrCPOF
mutant is accompanied by inhibition of the degradation of IxB normally induced
by
TNF. Under the influence of the expression of h-OTrCPOF, the phosphorylated
forms accumulate, as shown by the reactivity of the a-IxBa-S32 antibodies
(right
panel).
The h-OTrCP protein, on the other hand, activates the degradation of IKBa
(middle panel). The bottom panel, relating to the a-Myc antibody, is a control
panel showing the expression of the h-OTrCP and h-PTrCPOF proteins.
The h-OTrCP/IxB interaction was also confirmed by an
immunoprecipitation experiment.
To do this, Hela cells were transfected with a control pcDNA plasmid
expressing 0-galactosidase (0-Gal), the h-OTrCP protein (PTrCP) or the h-
PTrCPOF mutant (PTrCPAF), h-OTrCP and h-OTrCPOF having been fused to an
myc epitope at the C-terminal end. After 36 hours, the Hela cells were
stimulated
for 15 minutes with TNF in the presence of proteasome inhibitors (z-LLL-H)
(PALOMBELLA V. et al., Cell, 78, 773-789, 1994) (z-LLL-H + TNF; + reaction)
or left without stimulation (- reaction). The subsequent procedure then
consisted
either of a direct immunoblot after separation of the proteins in the cell
lyzate on
denaturing gel/SDS and transfer to a nitrocellulose membrane incubated with
a-IxBa-S32 antibodies (top panel), or to an immunoprecipitation with a-Myc
antibodies followed by an immunoblot, as indicated above, with the a-IxBa-S32
antibody or the a-IxBa antibody.
The results are indicated in Figure 9, in which the top panel shows the
results of the Western blot only and the bottom two panels show those of the
immunoprecipitation/Western blot, and the right panel gives the pattern of
migration of the phosphorylated forms induced by treatment with TNF on control
Hela cells.
By means of experiments involving the co-immunoprecipitation of the h-
PTrCP protein or the h-OTrCPOF fragment fused to the myc epitope, Figure 9
shows that only the phosphorylated form of IxBa, and not the non-
phosphorylated
form, is associated with the h-OTrCP protein (column 4). This association is
disclosed especially through the inhibition of degradation induced by the h-
PTrCPOF mutant (columns 5 and 6) and the use of proteasome inhibitors (z-LLL-
CA 02370098 2000-07-28
29
H).
Example 10: Interaction between the h-OTrCP protein and the ~-catenin protein
For this two-hybrid assay, the cDNAs coding for the proteins described
below were fused either to the Gal4 transcription activation domain (Ga14AD)
or to
the LexA DNA binding domain (LexABD):
-PTrCP = human PTrCP protein of the present invention,
- KIAA 0696 (PTrCP2) = human PTrCP protein isolated by ISHIKAWA et al.
(DNA Research, 5, 169-176, 1998),
- OCati_.130 = normal 0-catenin protein (N-terminal domain; 1-130),
-PCati_,130 S33-37AA = oncogenic P-catenin protein mutated on serine residues
S33 and S37 so that there is no phosphorylation,
- PCat = whole normal P-catenin protein.
The experimental results, which demonstrate that there is a specific
interaction of the novel human PTrCP protein with the 0-catenin protein, are
illustrated in Figure 10.
This two-hybrid assay shows that:
- the two proteins h-PTrCP and PCatl_.130 are capable of interacting,
- the h-PTrCP/PCatj-,130 interaction is removed when serine residues S33
and S37 are mutated to non-phosphorylatable residues (oncogenic P-catenin),
and
-PTrCP2 is not capable of reacting either with non-mutated P-catenin or
with mutated P-catenin.
It should be noted that an interaction is also observed between the whole P-
catenin protein and the h-PTrCP protein.
Example 11: Activation of the transcription of the TCF/LEF reporter eg ne by
the
expression of mutated ~-catenin or h-PTrCPAF in human 293 cells
HEK 293 cells were transfected with reporter vector Top-TK-Luci, which
contains a multimer of TCF-LEF sites, or reporter vector Fop-TK-Luci, which
contains an inactive control multimer of TCF-LEF sites. These constructs are
cotransfected with expression vector pCDNA3 (Invitrogen), either void as
control,
or expressing an oncogenic P-catenin fragment, namely P-catenin devoid of the
N-
terminal part, PCatON, or expressing the h-PTrCP protein or the PTrCPAF
fragment. The luciferase activity is measured 24 h after transfection and
standardized to a control Renilla luciferase activity obtained by the
cotransfection
of cells with vector RSV-Renilla (Promega).
CA 02370098 2000-07-28
The results obtained, which are given in Figure 11, show that the h-
OTrCPOF fragment induces the activation of a reporter gene controlled by a
TCF/LEF promoter, which responds to modifications in P-catenin expression
level
(Morin P.J. et al., 1997, Science, 275, 1787-1790). This indicates that the
5 degradation of P-catenin is inhibited by expression of the h-PTrCPOF mutant.
On
the other hand, as regards the KIAA 0696 protein, PTrCP2, in the same reporter
gene system, the positive effect induced by KIAA 0696 AF (PTrCP2AF) is much
weaker than that obtained with the equivalent PTrCPAF construct.
Taken together, these results therefore demonstrate that it is the h-PTrCP
10 protein of the invention, and not the KIAA 0696 protein, which is the
mediator of
P-catenin degradation.
Example 12: Study of the expression of the h- TrCP protein or the h- TrCPOF
fragment on the stability of the endo eg nous fi-catenin of Hela cells
15 Hela cells were transfected with the amounts of DNA indicated in Figure
12, expressing either the h-PTrCP protein or the h-PTrCPOF fragment fused to
the
myc epitope at the C-terminal end in a pcDNA vector (Invitrogen). After 24
hours,
the cells were lyzed and the cell proteins were separated on denaturing
polyacrylamide gel/SDS, transferred to a nitrocellulose membrane and incubated
20 either with an anti-p-catenin antibody (a-pCat), or with an anti-myc
antibody for
detecting the expression of the h-OTrCP protein or the h-PTrCPAF fragment (a-
Myc), by carrying out a Western blot (WB).
The results are indicated in Figure 12 and show that the expression of h-
PTrCP increases the degradation of P-catenin (middle column), whereas the
25 expression of the h-OTrCPAF mutant inhibits the degradation of P-catenin
and
leads to its accumulation in the cells (right column).
It should be noted that column C shows a control of non-transfected Hela
cells; the asterisk indicates, by the non-specific labeling of a cell protein
in the
Hela cell lyzate, that approximately the same amount of cell proteins has been
30 deposited in all the lanes.
The results corroborate those shown in the previous Example.
' CA 02370098 2000-07-28
1
SEQUENCE LISTING
<110> INSERM
<120> Human pTrCP protein for targeting proteins towards
proteasome degradation pathways
<140> PCT/FR99/00196
<141> 1999-01-29
<150> FR98 01100
<151> 1998-01-30
<150> FR98 15545
<151> 1998-12-09
<160> 8
<170> PatentIn Ver. 2.1
<210> 1
<211> 2151
<212> ADN
<213> Artificial sequence
<220>
<221> CDS
<222> (70)..(1776)
<220>
<223> Description of the artificial sequence ADNc
coding for human OTrCP protein
<400> 1
tgcgttggct gcggcctggc accaaagggg cggccccggc ggagagcgga cccagtggcc 60
tcggcgatt atg gac ccg gcc gag gcg gtg ctg caa gag aag gca ctc aag 111
Met Asp Pro Ala Glu Ala Val Leu Gln Glu Lys Ala Leu Lys
1 5 10
ttt atg aat tcc tca gag aga gaa gac tgt aat aat ggc gaa ccc cct 159
Phe Met Asn Ser Ser Glu Arg Glu Asp Cys Asn Asn Gly Glu Pro Pro
15 20 25 30
agg aag ata ata cca gag aag aat tca ctt aga cag aca tac aac agc 207
Arg Lys Ile Ile Pro Glu Lys Asn Ser Leu Arg Gln Thr Tyr Asn Ser
35 40 45
tgt gcc aga ctc tgc tta aac caa gaa aca gta tgt tta gca agc act 255
Cys Ala Arg Leu Cys Leu Asn Gln Glu Thr Val Cys Leu Ala Ser Thr
50 55 60
gct atg aag act gag aat tgt gtg gcc aaa aca aaa ctt gcc aat ggc 303
Ala Met Lys Thr Glu Asn Cys Val Ala Lys Thr Lys Leu Ala Asn Gly
65 70 75
act tcc agt atg att gtg ccc aag caa cgg aaa ctc tca gca agc tat 351
Thr Ser Ser Met Ile Val Pro Lys Gln Arg Lys Leu Ser Ala Ser Tyr
80 85 90
gaa aag gaa aag gaa ctg tgt gtc aaa tac ttt gag cag tgg tca gag 399
Glu Lys Glu Lys Glu Leu Cys Val Lys Tyr Phe Glu Gln Trp Ser Glu
95 100 105 110
CA 02370098 2000-07-28
2
tca gat caa gtg gaa ttt gtg gaa cat ctt ata tcc caa atg tgt cat 447
Ser Asp Gln Val Glu Phe Val Glu His Leu Ile Ser Gln Met Cys His
115 120 125
tac caa cat ggg cac ata aac tcg tat ctt aaa cct atg ttg cag aga 495
Tyr Gln His Gly His Ile Asn Ser Tyr Leu Lys Pro Met Leu Gln Arg
130 135 140
gat ttc ata act gct ctg cca gct cgg gga ttg gat cat atc gct gag 543
Asp Phe Ile Thr Ala Leu Pro Ala Arg Gly Leu Asp His Ile Ala Glu
145 150 155
aac att ctg tca tac ctg gat gcc aaa tca cta tgt gct gct gaa ctt 591
Asn Ile Leu Ser Tyr Leu Asp Ala Lys Ser Leu Cys Ala Ala Glu Leu
160 165 170
gtg tgc aag gaa tgg tac cga gtg acc tct gat ggc atg ctg tgg aag 639
Val Cys Lys Glu Trp Tyr Arg Val Thr Ser Asp Gly Met Leu Trp Lys
175 180 185 190
aag ctt atc gag aga atg gtc agg aca gat tct ctg tgg aga ggc ctg 687
Lys Leu Ile Glu Arg Met Val Arg Thr Asp Ser Leu Trp Arg Gly Leu
195 200 205
gca gaa cga aga gga tgg gga cag tat tta ttc aaa aac aaa cct cct 735
Ala Glu Arg Arg Gly Trp Gly Gln Tyr Leu Phe Lys Asn Lys Pro Pro
210 215 220
gac ggg aat gct cct ccc aac tct ttt tat aga gca ctt tat cct aaa 783
Asp Gly Asn Ala Pro Pro Asn Ser Phe Tyr Arg Ala Leu Tyr Pro Lys
225 230 235
att ata caa gac att gag aca ata gaa tct aat tgg aga tgt gga aga 831
Ile Ile Gln Asp Ile Glu Thr Ile Glu Ser Asn Trp Arg Cys Gly Arg
240 245 250
cat agt tta cag aga att cac tgc cga agt gaa aca agc aaa gga gtt 879
His Ser Leu Gln Arg Ile His Cys Arg Ser Glu Thr Ser Lys Gly Val
255 260 265 270
tac tgt tta cag tat gat gat cag aaa ata gta agc ggc ctt cga gac 927
Tyr Cys Leu Gln Tyr Asp Asp Gln Lys Ile Val Ser Gly Leu Arg Asp
275 280 285
aac aca atc aag atc tgg gat aaa aac aca ttg gaa tgc aag cga att 975
Asn Thr Ile Lys Ile Trp Asp Lys Asn Thr Leu Glu Cys Lys Arg Ile
290 295 300
ctc aca ggc cat aca ggt tca gtc ctc tgt ctc cag tat gat gag aga 1023
Leu Thr Gly His Thr Gly Ser Val Leu Cys Leu Gln Tyr Asp Glu Arg
305 310 315
gtg atc ata aca gga tca tcg gat tcc acg gtc aga gtg tgg gat gta 1071
Val Ile Ile Thr Gly Ser Ser Asp Ser Thr Val Arg Val Trp Asp Val
320 325 330
aat aca ggt gaa atg cta aac acg ttg att cac cat tgt gaa gca gtt 1119
Asn Thr Gly Glu Met Leu Asn Thr Leu Ile His His Cys Glu Ala Val
335 340 345 350
ctg cac ttg cgt ttc aat aat ggc atg atg gtg acc tgc tcc aaa gat 1167
Leu His Leu Arg Phe Asn Asn Gly Met Met Val Thr Cys Ser Lys Asp
355 360 365
CA 02370098 2000-07-28
3
cgt tcc att gct gta tgg gat atg gcc tcc cca act gac att acc ctc 1215
Arg Ser Ile Ala Val Trp Asp Met Ala Ser Pro Thr Asp Ile Thr Leu
370 375 380
cgg agg gtg ctg gtc gga cac cga gct gct gtc aat gtt gta gac ttt 1263
Arg Arg Val Leu Val Gly His Arg Ala Ala Val Asn Val Val Asp Phe
385 390 395
gat gac aag tac att gtt tct gca tct ggg gat aga act ata aag gta 1311
Asp Asp Lys Tyr Ile Val Ser Ala Ser Gly Asp Arg Thr Ile Lys Val
400 405 410
tgg aac aca agt act tgt gaa ttt gta agg acc tta aat gga cac aaa 1359
Trp Asn Thr Ser Thr Cys Glu Phe Val Arg Thr Leu Asn Gly His Lys
415 420 425 430
cga ggc att gcc tgt ttg cag tac agg gac agg ctg gta gtg agt ggc 1407
Arg Gly Ile Ala Cys Leu Gln Tyr Arg Asp Arg Leu Val Val Ser Gly
435 440 445
tca tct gac aac act atc aga tta tgg gac ata gaa tgt ggt gca tgt 1455
Ser Ser Asp Asn Thr Ile Arg Leu Trp Asp Ile Glu Cys Gly Ala Cys
450 455 460
tta cga gtg tta gaa ggc cat gag gaa ttg gtg cgt tgt att cga ttt 1503
Leu Arg Val Leu Glu Gly His Glu Glu Leu Val Arg Cys Ile Arg Phe
465 470 475
gat aac aag agg ata gtc agt ggg gcc tat gat gga aaa att aaa gtg 1551
Asp Asn Lys Arg Ile Val Ser Gly Ala Tyr Asp Gly Lys Ile Lys Val
480 485 490
tgg gat ctt gtg gct gct ttg gac ccc cgt gct cct gca ggg aca ctc 1599
Trp Asp Leu Val Ala Ala Leu Asp Pro Arg Ala Pro Ala Gly Thr Leu
495 500 505 510
tgt cta cgg acc ctt gtg gag cat tcc gga aga gtt ttt cga cta cag 1647
Cys Leu Arg Thr Leu Val Glu His Ser Gly Arg Val Phe Arg Leu Gln
515 520 525
ttt gat gaa ttc cag att gtc agt agt tca cat gat gac aca atc ctc 1695
Phe Asp Glu Phe Gln Ile Val Ser Ser Ser His Asp Asp Thr Ile Leu
530 535 540
atc tgg gac ttc cta aat gat cca gct gcc caa gct gaa ccc ccc cgt 1743
Ile Trp Asp Phe Leu Asn Asp Pro Ala Ala Gln Ala Glu Pro Pro Arg
545 550 555
tcc cct tct cga aca tac acc tac atc tcc aga taaataacca tacactgacc 1796
Ser Pro Ser Arg Thr Tyr Thr Tyr Ile Ser Arg
560 565
tcatacttgc ccaggaccca ttaaagttgc ggtatttaac gtatctgcca ataccaggat 1856
gagcaacaac agtaacaatc aaactactgc ccagtttccc tggactagcc gaggagcagg 1916
gctttgagac tcctgttggg acacagttgg tctgcagtcg gcccaggacg gtctactcag 1976
cacaactgac tgcttcagtg ctgctatcag aagatgtctt ctatcaattg tgaatgattg 2036
gaacttttaa acctcccctc ctctcctcct ttcacctctg cacctagttt tttcccattg 2096
gttccagaca aaggtgactt ataaatatat ttagtgtttt gccagaaaaa aaaaa 2151
CA 02370098 2000-07-28
4
<210> 2
<211> 569
<212> PRT
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : ADNc
coding for human PTrCP protein
<400> 2
Met Asp Pro Ala Glu Ala Val Leu Gln Glu Lys Ala Leu Lys Phe Met
1 5 10 15
Asn Ser Ser Glu Arg Glu Asp Cys Asn Asn Gly Glu Pro Pro Arg Lys
20 25 30
Ile Ile Pro Glu Lys Asn Ser Leu Arg Gln Thr Tyr Asn Ser Cys Ala
35 40 45
Arg Leu Cys Leu Asn Gln Glu Thr Val Cys Leu Ala Ser Thr Ala Met
50 55 60
Lys Thr Glu Asn Cys Val Ala Lys Thr Lys Leu Ala Asn Gly Thr Ser
65 70 75 80
Ser Met Ile Val Pro Lys Gln Arg Lys Leu Ser Ala Ser Tyr Glu Lys
85 90 95
Glu Lys Glu Leu Cys Val Lys Tyr Phe Glu Gln Trp Ser Glu Ser Asp
100 105 110
Gln Val Glu Phe Val Glu His Leu Ile Ser Gin Met Cys His Tyr Gln
115 120 125
His Gly His Ile Asn Ser Tyr Leu Lys Pro Met Leu Gln Arg Asp Phe
130 135 140
Ile Thr Ala Leu Pro Ala Arg Gly Leu Asp His Ile Ala Glu Asn Ile
145 150 155 160
Leu Ser Tyr Leu Asp Ala Lys Ser Leu Cys Ala Ala Glu Leu Val Cys
165 170 175
Lys Glu Trp Tyr Arg Val Thr Ser Asp Gly Met Leu Trp Lys Lys Leu
180 185 190
Ile Glu Arg Met Val Arg Thr Asp Ser Leu Trp Arg Gly Leu Ala Glu
195 200 205
Arg Arg Gly Trp Gly Gln Tyr Leu Phe Lys Asn Lys Pro Pro Asp Gly
210 215 220
Asn Ala Pro Pro Asn Ser Phe Tyr Arg Ala Leu Tyr Pro Lys Ile Ile
225 230 235 240
Gin Asp Ile Glu Thr Ile Glu Ser Asn Trp Arg Cys Gly Arg His Ser
245 250 255
Leu Gln Arg Ile His Cys Arg Ser Glu Thr Ser Lys Gly Val Tyr Cys
260 265 270
Leu Gln Tyr Asp Asp Gln Lys Ile Val Ser Gly Leu Arg Asp Asn Thr
275 280 285
Ile Lys Ile Trp Asp Lys Asn Thr Leu Glu Cys Lys Arg Ile Leu Thr
290 295 300
CA 02370098 2000-07-28
Gly His Thr Gly Ser Val Leu Cys Leu Gln Tyr Asp Glu Arg Val Ile
305 310 315 320
Ile Thr Gly Ser Ser Asp Ser Thr Val Arg Val Trp Asp Val Asn Thr
325 330 335
Gly Glu Met Leu Asn Thr Leu Ile His His Cys Glu Ala Val Leu His
340 345 350
Leu Arg Phe Asn Asn Gly Met Met Val Thr Cys Ser Lys Asp Arg Ser
355 360 365
Ile Ala Val Trp Asp Met Ala Ser Pro Thr Asp Ile Thr Leu Arg Arg
370 375 380
Val Leu Val Gly His Arg Ala Ala Val Asn Val Val Asp Phe Asp Asp
385 390 395 400
Lys Tyr Ile Val Ser Ala Ser Gly Asp Arg Thr Ile Lys Val Trp Asn
405 410 415
Thr Ser Thr Cys Glu Phe Val Arg Thr Leu Asn Gly His Lys Arg Gly
420 425 430
Ile Ala Cys Leu Gln Tyr Arg Asp Arg Leu Val Val Ser Gly Ser Ser
435 440 445
Asp Asn Thr Ile Arg Leu Trp Asp Ile Glu Cys Gly Ala Cys Leu Arg
450 455 460
Val Leu Glu Gly His Giu Glu Leu Val Arg Cys Ile Arg Phe Asp Asn
465 470 475 480
Lys Arg Ile Val Ser Gly Ala Tyr Asp Gly Lys Ile Lys Val Trp Asp
485 490 495
Leu Val Ala Ala Leu Asp Pro Arg Ala Pro Ala Gly Thr Leu Cys Leu
500 505 510
Arg Thr Leu Val Glu His Ser Gly Arg Val Phe Arg Leu Gln Phe Asp
515 520 525
Glu Phe Gln Ile Val Ser Ser Ser His Asp Asp Thr Ile Leu Ile Trp
530 535 540
Asp Phe Leu Asn Asp Pro Ala Ala Gln Ala Glu Pro Pro Arg Ser Pro
545 550 555 560
Ser Arg Thr Tyr Thr Tyr Ile Ser Arg
565
<210> 3
<211> 19
<212> ADN
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : sense primer
<400> 3
ccaaactgcg tataacgcg 19
' ~ =.
CA 02370098 2000-07-28
6
<210> 4
<211> 20
<212> ADN
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : antisense primer
<400> 4
ggtgaatcaa cgtgtttagc 20
<210> 5
<211> 20
<212> ADN
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : sense primer
<400> 5
ggatgatgta tataactatc 20
<210> 6
<211> 25
<212> ADN
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : antisense primer
<400> 6
tttatcccag atcttgattg tgttg 25
<210> 7
<211> 30
<212> ADN
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : primer
<400> 7
ccaggatcct tatacaacat tgacagcagc 30
<210> 8
<211> 29
<212> ADN
<213> Artificial sequence
<220>
<223> Description of the artificial sequence : primer
<400> 8
ccaggatcct tagtcccaga tgaggattg 29
